Alkali-Stable Protein A Chromatography Matrix

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current affinity chromatography matrices containing protein A ligands face challenges with alkaline stability during cleaning procedures, limiting the effectiveness of NaOH concentrations and resulting in reduced capacity and stability, which hampers the efficient purification of therapeutic antibodies.

Innovation Solution

Development of a mutant Fc-binding polypeptide of Staphylococcus Protein A with specific mutations, such as replacing the asparagine residue at position 11 with amino acids like glutamic acid or lysine, and multimers thereof, which are covalently coupled to a porous support, enhancing alkaline stability and binding capacity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If high concentrations of NaOH are used for cleaning the affinity chromatography matrix, then cleaning effectiveness is improved, but the protein A ligand stability deteriorates

Engineering Contradiction:
Improvecleaning effectivenessVSAvoidligand stability
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid sequence of protein A through site-directed mutagenesis. Specifically, asparagine residues at positions 11, 43, and 50 are mutated to amino acids with higher alkaline stability (such as glutamic acid, lysine, or alanine). This changes the chemical parameters of the ligand to resist alkaline degradation during cleaning procedures, allowing the matrix to withstand high NaOH concentrations without losing ligand stability.

Inventive Principle:
Principle #35Parameter changes

2Object-generated harmful factors

If the affinity chromatography matrix is exposed to alkaline cleaning solutions, then contaminant removal is improved, but the binding capacity deteriorates

Engineering Contradiction:
Improvecontaminant removalVSAvoidbinding capacity
Core Design Contradiction:
Object-generated harmful factorsVSQuantity of substance

Solution Approach 1:

The patent changes the chemical parameters of the protein A ligand by introducing mutations at critical asparagine residues. These mutations increase the pH stability of the ligand, allowing it to maintain its binding capacity even after exposure to alkaline cleaning solutions. The mutated ligands retain their ability to bind immunoglobulins while being resistant to alkaline-induced capacity loss.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If conventional protein A ligands are used in affinity chromatography, then immunoglobulin binding is achieved, but alkaline stability deteriorates

Engineering Contradiction:
Improveimmunoglobulin bindingVSAvoidalkaline stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid composition of protein A. Specifically, asparagine residues at positions 11, 43, and 50 are replaced with amino acids that have higher resistance to alkaline hydrolysis. This changes the chemical stability parameters of the ligand while preserving its immunoglobulin binding function, as the mutations are designed to not interfere with the binding interface.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite material structures by combining mutated protein A domains with support matrices. The mutated ligands are coupled to various supports (such as agarose, sepharose, or synthetic polymers) to create composite affinity media that exhibit both high immunoglobulin binding capacity and enhanced alkaline stability. The composite structure allows the ligand to maintain its function while gaining resistance to alkaline conditions.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The mutant polypeptides and multimers exhibit improved alkaline stability and maintained immunoglobulin binding properties, allowing for high dynamic binding capacity and efficient alkaline cleaning, thus facilitating economically viable purification of antibodies.

Implementation Method 1

Fc-binding polypeptide comprising a mutant of a parental Fc-binding domain

Methodology Applied
Scientific EffectAffinity binding: Adsorption

Implementation Method 2

multimers thereof, which are covalently coupled to a porous support

Methodology Applied
Scientific EffectCovalent coupling: Chemical Bonding

Data Source

PatentUS12134633B2Separation matrix
Publication Date: 2024.11.05 CYTIVA BIOPROCESS R&D AB
  • US12134633B2 patent drawing
  • US12134633B2 patent drawing
  • US12134633B2 patent drawing

AI summary

The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:a) the ligands comprise multimers of alkali-stabilized Protein A domains, andb) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.